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Hepatitis C virus (HCV) is the major cause of chronic liver disease as well as the major indication for liver transplantation
worldwide. Current standard of care is not completely effective, not administrable in grafted patients, and burdened by several
side effects. This incomplete effectiveness is mainly due to the high propensity of the virus to continually mutate under the
selective pressure exerted by the host immune response as well as currently administered antiviral drugs. The E2 envelope surface
glycoprotein of HCV (HCV/E2) is the main target of the host humoral immune response and for this reason one of the major
variable viral proteins. However, broadly cross-neutralizing monoclonal antibodies (mAbs) directed against HCV/E2 represent
a promising tool for the study of virus-host interplay as well as for the development of effective prophylactic and therapeutic
approaches. In the last few yearsmany anti-HCV/E2mAbs have been evaluated in preclinical and clinical trials as possible candidate
antivirals, particularly for administration in pre- and post-transplant settings. In this review we summarize the antigenic and
structural characteristics of HCV/E2 determined through the use of anti-HCV/E2 mAbs, which, given the absence of a crystal
structure of this glycoprotein, represent currently the best tool available.
1. Introduction: Functions of
HCV Glycoproteins
The hepatitis C virus (HCV) glycoproteins E1 and E2 are
the most important targets of neutralizing antibodies (Abs).
This is a direct consequence of their roles in mediating entry
of the virus into susceptible cells in a pH- and clathrin-
dependent manner [1–5]. The two genes encoding the HCV
glycoproteins lie in the N-terminal part of the HCV genome.
The glycoproteins are expressed initially as part of the virus
polyprotein, with the mature proteins being released by the
action of the host cellular proteinases signal peptidase and
signal peptide peptidase [6]. Depending on virus isolate,
mature, cleaved E1 protein possesses 192 amino acids and
E2 between 363 and 369 amino acids. The glycoproteins
form heterodimers through interactions between their trans-
membrane domains, each chaperoning the folding of the
other during synthesis [7, 8]. Amino acid variation in E1 and
E2 proteins exceeds 37% among infectious primary isolates,
highlighting the extreme genetic diversity that is tolerated in
the E1 and E2 genes [9]. The greatest amino acid variation
is observed in three hypervariable regions (HVRs) in the
E2 protein [10–12]. HVR1 is a 26-27 amino acid region
at the extreme N-terminus of E2 and displays the greatest
variability in the HCV polyprotein. HVR2 is proximal to the
CD81 binding regions of E2, while the intergenotypic variable
region (IgVR) lies closer to the transmembrane domain of
E2 [12]. Despite this heterogeneity, both proteins possess
conserved N- and O-linked glycans, and there is evidence
of extensive glycosylation on the surface of both proteins
[13, 14]. E2 is the major receptor binding protein, interacting
with cell surface molecules CD81, SR-BI, and occludin [15–
17]. The interaction between E2 and cell surface receptors
has been well described: the binding surface with CD81 is a
discontinuous surface encompassing three highly conserved
regions of the E2 protein [18–20], while the interaction
with SR-BI is believed to be mediated by the N-terminal
hypervariable region (HVR1) of the E2 protein [21]. Blockade
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of receptor interactions is likely to be the main action of
neutralizing Abs.
2. Structure of E1 and E2
There is little direct evidence for the structure and domain
architecture of the E1 and E2 glycoproteins. Efforts to
crystalize these proteins have so far yielded no accurate
structure. As a result, attempts to assign domain structures
to these proteins have used a combination of computational
models [22] and biochemical analyses [23]. Early studies of
the structure of E2 mapped the HCV primary amino acid
sequence onto the crystal structure of a prototype Flavivirus
E protein possessing a type II fusion protein architecture
[22]. Recent analyses have mapped the disulphide bridging
patterns within the ectodomain of E2, finding patterns con-
sistent with a type II fusion protein [23]. In this study, three
domains were defined, relating to the three classical domains
of Flavivirus glycoproteins, DI, DII, and DIII. In this model
DI is discontinuous and features an immunoglobulin fold
including the CD81 binding site. DII is predicted to possess a
hydrophobic fusion peptide.However,members of the genera
Hepacivirus and Flavivirus are only remotely related. Studies
describing the crystal structure of the Pestivirus E2 protein
have queried the validity of assigning a type II classification
to the HCV glycoprotein [24, 25]. The Pestivirus protein
possesses a previously undescribed four domain structure,
with four contiguous domains. While this class of structure
cannot be assigned to HCV/E2 yet, this data illustrates the
possibility that the HCV glycoprotein might belong to an as-
yet undescribed class of fusion proteins.
The structure of E1 has been even more intractable.
Expressed in the absence of E2, E1 aggregates and does not
fold correctly, making structural analysis impossible [26, 27].
This is consistent with reports that E1 might contain the
hydrophobic peptide required for envelope fusion [28, 29]. In
the absence of direct structural evidence, many studies have
investigated the antigenic structure of the E1 and E2 proteins
to elucidate its architecture.
3. The Antigenic Structure of
HCV/E2 Glycoprotein
There is a wealth of data describing the role of neutralizing
Abs in protecting against HCV infection, which has recently
been the focus of reviews by Edwards et al. [30] and Fafi-
Kremer et al. [31]. Here we will focus on the binding of Abs
to specific epitopes in HCV/E2 and the different properties of
Abs targeting these epitopes.
Glycoprotein E2 appears to be the more immuno-
genic of the two HCV glycoproteins [53]. Studies isolating
monoclonal antibodies (mAbs) from HCV-infected indi-
viduals and experimentally immunized animals have pre-
dominantly isolated anti-E2 Abs. Epitopes can be classified
as either linear (recognizing linear peptides with contact
residues that are only a few residues apart) or conformation
sensitive (with contact residues distantly distributed along
the primary amino acid sequence but proximal in the three-
dimensional space occupied by the protein). Many of the
Abs elicited by immunization with recombinant forms of the
glycoproteins recognize linear epitopes [32, 54]. In contrast,
mAbs isolated from infected humans more often recognize
conformation-sensitive epitopes [43, 46, 55] (Tables 1 and 2).
Thus the nature of the immunogen is critical to the quality
of the Ab response produced. This is also reflected in the
neutralizing capacity ofmAbs isolated by the two approaches,
while many human mAbs possess neutralizing potency
[44, 56–58], murine mAbs recognizing linear epitopes have
restricted specificity and no neutralizing properties [3].
Initial attempts tomapmurinemAbs utilized overlapping
panels of linear peptides designed from reference isolates
[32]. This identified a range of epitopes that were accessible
on recombinant proteins and virus-like particles across both
E1 and E2 that were immunogenic when animals were immu-
nized with recombinant proteins [54]. With some notable
exceptions, mAbs recognizing linear peptides demonstrated
restricted patterns of recognition and neutralization.Thiswas
particularly notable for the mAbs recognizing epitopes in
HVR1 but also for other Abs recognizing linear epitopes [3]
(Table 2).
3.1. The HVR1 as a Target for Abs. Following early studies
of the Ab response to HCV, the HVR1 was thought to be
the major immunodominant neutralization region in the E2
protein. Abs directed to HVR1 were isolated from infected
chimpanzees and protected against infection [59]. This was
supported by indirect evidence that sequence variability in
theHVR1 during chronic infection corresponded to selection
of particular HVR1 variants, suggesting that Ab neutraliza-
tion drives selection of HVR1 quasispecies [60]. HVR1 was
subsequently identified to have a direct role in entry, binding
to SR-BI and augmenting infectivity [17, 21, 61, 62]. HVR1
also modulates neutralization by Abs targeting the conserved
CD81 binding site [63], suggesting that the observed genetic
heterogeneity might contribute to persistence in the presence
of host broadly neutralizing Abs. HVR1 acts as an immune
decoy and prevents generation of a protective Ab response
to conserved epitopes in regions essential for E2 function
[63]. Mapping has revealed multiple epitopes in the HVR1
region, all of which are restricted in their reactivity. These
Abs have different properties. Abs targeting the very N-
terminus of E2 have no neutralizing activity [3]. In contrast
the rat mAb 9/27 inhibits binding of E2 to SR-BI and potently
neutralizes infectivity of genotype 1a strains [3, 64].ThismAb
mapped to an epitope in the C-terminal half of the 27-amino
acid HVR1 as did other HVR1-specific Abs that neutralized
infection [65]. More recently, screening of large panels of
mAbs generated by immunization of mice has identified
neutralizingAbswith epitopes in theC-terminal end ofHVR1
(J6.36, J6.103, and H77.16), which inhibit E2 interaction with
SR-BI (Table 1) [38]. These studies highlight not only the
potential for anti-HVR1 Abs for preventing infection but
also the limitations of restricted reactivity due to sequence
variation in primary HCV isolates across the linear epitopes
in this region, as recently confirmed in phase 1B clinical trials
[66].
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Table 1: Schematic representation of the regions targeted by anti-HCV/E2 mAbs. Involved domains (DI, DII and DIII as well as the stem
region) of HCV/E2 have been evidenced. In particular, DI has been described to be a discontinuous region containing the CD81 binding site;
DII is predicted to possess the fusion peptide and DIII has been recently described to contain antigenic neutralization epitopes and to be
involved in heterodimerization with E1.
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[26, 54, 32]
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[26]
E1-E2
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N-terminal
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Table 2: Synopsis of broadly anti-HCV/E2 neutralizing mAbs.
mAb Origin Epitope Genotype breadth ofneutralization (HCVpp)
Genotype breadth of
neutralization
(HCVcc)
In vivo tested Escapegeneration References
9/27 Rat Linear 1a 1a, 2a No N.D. [3, 28, 32]
HCV-AB68 Human Conformational 1b N.D. Yes Yes [33]
AP33
(MRCT10.v362)
Murine
(humanized) Linear 1–6 1a, 2a Yes Yes [34–36]
3/11 Rat Linear 1, 2, 4, 5, 6 1a, 2a No N.D. [3, 28]
2/69a Rat Conformational 1a, 2a 1a No N.D. [3, 28, 37]
11/20 Rat Conformational 1 N.D. No N.D. [3, 28]
1/39 Rat Conformational 1 N.D. No N.D.
H77.16 Murine Conformational N.D. 1a No N.D.
[38]
H77.39 Murine Conformational N.D. 1a No N.D.
J6.36 Murine Conformational N.D. 2a No N.D.
J6.103 Murine Conformational N.D. 2a No N.D.
HCV1 Human Linear 1a, 1b, 2b, 3a, 4a 2a Yes Yes [39]
#8 Murine Conformational N.D. 1a No N.D. [40, 41]
HC-1 Human Conformational 1a, 1b 2a No No [42]
HC-11 Human Conformational N.D. 2a No Yes
CBH-5 Human Conformational 1–6 2a, 2b No N.D. [43, 44]
CBH-7 Human Conformational 1, 2, 4 2a, 2b No N.D.
A8 Human Conformational 1–6 2a No N.D. [45]
1:7 Human Conformational 1–6 2a No N.D.
AR2A Human Conformational 1a, 2a, 2b, 4, 5 No No N.D. [46]
AR3A Human Conformational 1–6 1–6 Yes N.D. [26, 46]
AR3B Human Conformational 1a, 1b, 2a, 2b, 4, 5 2a Yes N.D.
[46]AR3C Human Conformational 1a, 1b, 2a, 2b, 4, 5 2a No N.D.
AR3D Human Conformational 1a, 1b, 2a, 2b, 4, 5 2a No N.D.
AR4A Human Conformational 1–6 1–6 Yes N.D. [26]
AR5A Human Conformational 1a, 1b, 4, 5, 6 1a, 2a, 4, 5, 6 No ND
HC33.1 Human Linear N.D. 1a–6a No N.D.
[47]
HC33.4 Human Linear N.D. 1a–6a No N.D.
HC33.8 Human Linear N.D. 1a, 2a, 4a No N.D.
HC33.29 Human Linear N.D. 1a, 2a, 4a No N.D.
mu5B3
(hu5B3.v3)
Murine
(humanized) Linear 1a, 1b, 2a 2a No Yes [36]
HC84-1 Human Conformational 1a 1a–6a No No [48]
HC84-27 Human Conformational 1a 1a–6a No No
e20 Human Conformational 1a, 1b, 2a, 2b, 4, 5 (N.D.on 3 and 6) 1a, 2a No N.D. [49–51]
e137 Human Conformational 1a, 1b, 2a, 2b, 4, 5 (N.D.on 3 and 6) 1a, 2a No N.D. [50–52]
ND: not determined.
3.2. Epitopes in the 412–423 Amino Acid Region (Epitope I).
Immediately downstream of the HVR1 is a highly conserved
region of the HCV genome. Early studies identified murine
mAbs that bound to this region in proteins representing
genetically diverse HCV strains [28, 32, 54]. This region was
established to play an important role in forming complexes
of E2 with CD81 [28] and to have a direct role in entry by
mediating CD81 binding [19]. Murine mAbs (AP33 and 3/11)
that recognized a peptide defined as amino acids 412–423
(also known as epitope I) of the HCV polyprotein were found
to efficiently neutralize entry (Table 1) [3, 34]. Although
these Abs were originally thought to recognize the same
conserved epitope, molecular dissection of their respective
contact residues revealed that they recognize overlapping epi-
topes with different neutralizing potentials [35]. Specifically,
AP33 possessed very high neutralizing potency, binding to
Clinical and Developmental Immunology 5
contact residues at positions L413, N415, G418, andW420. In
contrast, mAb 3/11 formed interactions with residues N415,
W420, and H421 and neutralized the same panel of viruses
with lower potency [35]. The interaction of AP33 with its
epitope was subsequently confirmed by solving the crystal
structure of the E2 peptide in complex with AP33 [67, 68].
Other mAbs recognizing this region have more recently been
described, including human mAb HCV1 [39], which binds
predominantly at positions L413 and W420 [69]. Isolation of
mouse Abs using a neutralization screening procedure also
isolated a broadly neutralizing mAb, H77.39, that recognized
this region [38]. Screening this mAb with a random mutant
E2 library resulted in residues N415 and N417 as important in
recognition. Indeed, of all 78 anti-E2 mAbs screened in this
assay, this was by far themost potent at neutralizing infection.
As well as blockading interaction with CD81, H77.39 also
inhibited SR-BI binding to E2, suggesting that the proximity
of this mAb binding to the HVR1 resulted in two combined
modes of neutralizing action. Together these data confirm
that discrete, overlapping neutralization epitopes exist in this
highly conserved region of E2. Interestingly, all mAbs so far
analyzed require W420 as a contact residue. This residue
has been described to be critically important in binding to
CD81 [19], making up one of the discontinuous regions of the
conformation sensitive CD81 binding site [70]. Blockade of
the interaction with CD81 is the likely mode of neutralization
of these Abs, and it is clear that this region of the protein plays
a critical role in the entry pathway of HCV.
Studies of the prevalence of Abs directed to this region
in chronically infected individuals have revealed a very low
seroprevalence [37, 71], suggesting that this region is not
naturally immunogenic. Importantly, while around 2.5% of
chronically infected individuals raised an Ab response to
the region, less than 1% of infections resulted in an Ab
response containing Abs sharing epitope specificity with
AP33 [71]. Abs directly purified from those patients with a
detectable response to the region spanning 412–423 amino
acids were able to broadly and potently neutralize infection,
highlighting the potency of Abs to this region. In an alterna-
tive approach, Abs purified from hyper-immune globulin by
reactivity to a peptide corresponding to the 412–419 amino
acid region efficiently neutralized entry, demonstrating that
epitopes without the conserved tryptophan at amino acid
420 also contribute to neutralization. Together these studies
demonstrate that the Abs to this region have potential for
therapeutic administration and vaccine design.
3.3. The Discontinuous CD81 Binding Region as a Target for
Abs. While locating linear epitopes recognized by mAbs,
such as AP33, is a relatively straightforward process using
overlapping peptides, identification of the contact residues
of conformation-sensitive Abs targeting the discontinuous
CD81 binding site requires a combination of techniques. We
and others have mapped a range of Abs directed to the HCV
glycoproteins, using a combination of single residue alanine-
scanning mutagenesis, mimotope affinity selection from
random phage-displayed peptide libraries, mapping using
randomyeast-display libraries, and competition analysis with
mAbs recognizing linear peptides [38, 44–46, 49, 52]. These
analyses identified the discontinuous CD81 binding site as
a key conserved neutralization determinant. Analysis of the
neutralizing potential of Abs against all six major genotypes
of HCV highlighted key conserved amino acids that were
common to the interaction with CD81 and neutralizing
mAbs. One important region of E2 that is involved in this
interaction was described to be between amino acids 523
and 535 [19]. Many of the broadly neutralizing human anti-
E2 mAbs recognize one of a small number of conserved
residues in this region, including G523, Y527, W529, G530,
and D535 (Table 1) [44–46, 49, 52]. However, similarly to
mAbs directed to the linear region 412–423, different mAbs
possess slightly different contact residues. This region is
consistent with “Antigenic Domain B” defined by Keck and
colleagues and “Antigenic Region 3” (AR3) as defined by Law
et al. [46, 72]. This region appears to be immunogenic in
natural infection, as human mAbs to overlapping epitopes
in this region have been isolated from independent patients,
using affinity selection from phage-displayed Ab libraries
[46, 55, 73] or transformation of human B cells from HCV
infected individuals [44, 72, 74]. Neutralizing murine mAbs
to this region has also been isolated following immunization
with E2 [38]. Interestingly, there is a third class of Abs
targeting this region typified by a human mAb isolated from
a phage display library, e137 [52, 75]. This mAb has a unique
epitope specificity that overlaps both the 412–423 and the
523–535 neutralizing regions. Key contact residues are T416,
W420, W529, G530, and D535, suggesting that the AR3
and the epitope cluster typified by AP33 are proximal on
the surface of the E2 protein associated with virions [52].
Another unique epitope overlapping the CD81 binding site
has also recently been described. Immunization of an alpaca
with recombinant E2 resulted in the production of anti-E2
heavy chain-only Abs (HCAbs) with specificity for the E2
ectodomain [76]. Cloning of the antigen binding domains
of these Abs (nanobodies) identified nanobody D03 that
possessed epitope specificity for the conserved amino acids
N415, G523, and T526. This nanobody was able to both
neutralize infectivity and prevent cell-to-cell transmission of
HCV. Together these data suggest that the CD81 binding site
is a promising target for administration of therapeutic Abs. It
is highly conserved [19] and there is an absolute requirement
for CD81 binding for entry all strains so far described [5, 9,
21, 77].This region is also resistant to the emergence of escape
mutations [42], indicating that therapy might not suffer from
short-term efficacy.
3.4. Other Epitopes in E2. In addition to this major antigenic
region overlapping the CD81 binding site, other antigenic
domains have also been defined in independent studies by
reactivity to human mAbs. A region containing a type-
restricted neutralization epitope (AR2) closely overlaps the
“Antigenic Domain C,” defined by the mAbs CBH-7 and
AR2A, centred on an asparagine residue at position 540 [46,
72].While this epitope region is not extensively characterized,
competition assays revealed that this epitope is discrete
from those recognized bymurine conformation-independent
mAbs. The restricted neutralization observed by CBH-7 and
AR2A suggests that amino acids positions tolerant to change
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are the target of these Abs. From this it can be inferred
that these regions of E2 are unlikely to play a key role in
the entry cascade and therefore are unlikely to be a good
choice to pursue for therapeutic intervention. An additional
antigenic region, AR1, has also been identified, with contact
residues around V538 and N540. This too overlaps with the
epitope of CBH-7 [46] but has no neutralizing activity. It is
striking that despite the differences in phenotype between
Abs representing different antigenic regions, their epitopes
all appear to cluster around a small area of the surface of
E2, in the proposed DI [23]. Structural analysis is required
to elucidate if this is the case, or whether the common
competition with CBH-7 is due to steric hindrance.
Recently two additional antigenic regions have been pro-
posed. Having been well established that the CD81 binding
site is the most likely target of neutralizing Abs isolated
from human Ab libraries, Giang and colleagues pre-blocked
the E2 glycoprotein with known CD81-binding site Abs
before selecting a phage-displayed Ab library for affinity to
the protein complex [26, 78]. This yielded novel Abs with
specificity for epitopes outside the CD81 binding site, binding
to regions defined as “Antigenic Region 4 and 5” (AR4 and
AR5). Notably, mAb AR4A potently neutralized a range of
genetically diverse strains and was able to limit infection in
vivo [26]. Binding of AR4A and AR5A was dependent on the
presence of E1 as well as E2, suggesting that the conformation
of the heterodimer is important to their epitopes. Indeed,
some mutations in E1 affected binding of both of these
Abs. However, distinct residues in E2 were found to be
important for each of these Abs, with D698 being essential
for AR4A binding, while R639 was essential for mAb AR5A
binding (Table 1). These epitopes are located in an otherwise
undescribed cluster in a membrane proximal region in E2.
However, in common with AR1, AR2 and AR3, AR5A were
observed to compete with mAb CBH-7, placing the epitope
of this human mAb in a central position overlapping the
different antigenic faces of E2. In contrast, AR4A did not
compete with CBH-7, emphasizing the unique nature of this
Ab epitope.
4. Nonneutralizing/Interfering Anti-HCV/E2
Abs and Topography of Targeted Epitopes
4.1. The Concept of Ab-Mediated Interference. The concept of
nonneutralizing/interfering Abs elicitation by pathogens is
historically well known. It was first hypothesized byDulbecco
et al. in 1956 analyzing the Ab-mediated neutralization of
two animal viruses (Western equine encephalomyelitis and
poliomyelitis type 1). In particular, they had observed an
inhibition of virus neutralization exerted by some serum
samples that probably contained Abs able to inhibit the
binding of neutralizing Abs without affecting virus infectivity
[79].
In the following years, this phenomenon has acquired
a gradually relevant interest giving its possible role in the
establishment of chronic viral infections, in which the virus
persists notwithstanding the presence of an excess of neu-
tralizing Abs. In particular, very recently, its role is widely
debated for HCV and other hypervariable viruses (such
as Influenza and HIV) as a further escape mechanism to
continually overcome the humoral immune response of the
host [80–86].
At present mAbs represent the best available tools to
study the role of nonneutralizing/interfering B-cell epitopes,
giving their standardized behavior compared to polyclonal
preparations (i.e., specific reactivity with individual antigenic
determinants) and indeed the ideal probes for studying the
spatial relationship or topography of viral targeted epitopes
and their role in neutralization [87].
4.2. Role of Nonneutralizing/Interfering Abs in HCV Infection.
The hypothesis of the mechanism of Ab-mediated interfer-
ence in HCV infection was firstly investigated using anti-
HCV/E2 mAbs isolated from a chronically HCV-infected
patient [88]. In particular, we observed that binding of
monoclonal Fabs to HCV/E2 caused conformational changes
modifying Fab-binding patterns and reducing, with a nega-
tive synergistic effect, Fab-mediated neutralization of binding
(NOB) activity to the CD81 receptor. Indeed, our study
hypothesized that some Ab clones have the potential to
modify HCV/E2 conformation and that, in this state, binding
of this glycoprotein to its cellular target is less prone to
inhibition by some Ab clones.
More recently, a paper by Zhang et al. finely demonstrated
our hypothesis and mapped the HCV/E2 B-cell epitopes
involved [89]. In particular, they observed that neutralizing
Abs, directed against an E2 region involved in HCV binding
to CD81, and in particular encompassing epitope I, could be
hindered by the presence of nonneutralizing Abs which bind
residueswithin epitope II, spanning amino acid residues 434–
446. Interestingly, they observed that blocking or deletion
of these interfering epitope II-specific Abs not only raised
the neutralizing titer of HCV-positive sera containing both
epitope I- and epitope II-specific Abs but also uncovered a
broader cross-genotype neutralizing response.
Recently, we have confirmed the observation of Zhang
et al. using anti-HCV/E2 mAbs and analyzing their activity
in vitro through HCVcc and HCVpp neutralization assays
[50]. In particular, it has been found that among the mAbs
isolated from a chronically HCV-infected patient, the human
mAb e509, recognizing residues within epitope II, was able to
interfere with the broadly neutralizing activity of the mouse
mAb AP33, which is known to bind the epitope I region.
In particular, competition assays suggest that the binding of
e509 interferes with AP33 activity by sterically hindering its
binding to its epitope or possibly inducing conformational
changes on E2 that inhibit AP33 interaction.
On the other hand, the activity of two other broadly cross-
neutralizing mAbs, e20 and e137, was not minimally affected
by e509. One of the reasons for this lack of interference is
probably that e20 and e137 mostly bind residues targeted by
neutralizing Abs in another CD81-binding region of HCV/E2
(in particular that encompassing amino acid residues 529–
535) outside epitope I and therefore potentially less subjected
to the interfering effect of epitope II-directed Abs. Moreover,
in contrast to AP33, e20 and in particular e137 also bind
residues within the interfering epitope II, but at higher
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affinity than e509, thus displacing it from HCV/E2. In fact,
as speculated by Duan et al. and also recently confirmed in
the work by Keck et al., the neutralization ability appears to
be correlated with the overall binding affinity of these mAbs
to epitope II [40, 47]. Furthermore, similar to e20 and e137, it
has been described that somemAbs which bind the antigenic
domain B of HCV/E2 also contain residues located within
epitope II (Table 1) [42].
In contrast to these findings, we recently observed that
different Abs targeting the region encompassing epitope II
not only neutralized HCVpp and HCVcc infection but aug-
mented neutralization mediated by Abs targeting the region
encompassing epitope I. In particular, for these studies, the
murine and rat mAbs AP33 and 2/69a (with the last one
targeting epitope II), as well as human immunoglobulin
fractions affinity purified on linear peptides representing
distinct HCV/E2 domains clustering within the regions 412–
426 and 434–446, were used. Combining these Abs together,
we failed to demonstrate any inhibition between these two
groups of Abs [37]. These results provided evidence that
interference by nonneutralizing Abs, at least to the region
encompassing residues 434–446, is not a mechanism for
HCV persistence in chronically infected individuals, as it had
been originally proposed by Zhang and colleagues.
However, this study confirmed, as previously observed by
other groups and by patient sera analysis of binding to epitope
I and epitope II, that these two regions are co-immunogenic
despite being both recognized by the sera of only a small
subset of patients [35, 89]. Indeed, this observation further
confirms the known low immunogenicity of the epitope I
region compared to epitope II, considering also the less
conserved nature of this last epitope [35]. Furthermore, these
data confirm the mostly conformational nature of epitope II
as previously suggested by our data and by previous structural
studies [23, 90]. In fact, as expected, binding assays per-
formed on peptides spanning conformational regions could
not completely predict their immunogenicity as Abs directed
against conformational epitopes could not be detected.
Indeed, we found that, depending on the infected individual,
Abs targeting the region encompassing epitope II could differ
in phenotype, according to their epitope specificity, or could
exhibit a dual phenotype [37].
In accordance with these findings, Keck et al. described
anti-HCV/E2 human mAbs binding conformation-sensitive
epitopes encompassing also some residues within the 434–
446 interfering region. These mAbs are broadly neutralizing
and do not lead to viral escape mutants, demonstrating
the functional importance of their epitopes. The authors
conclude that not all Abs directed against epitope II are
interfering and that this activity could be limited to Abs
recognizing linear epitopes within it [58].
Furthermore, in a more recent work, Keck et al. isolated
humanmAbs (namedHC33) directed against a peptide span-
ning epitope I region possessing varying neutralizing activity
against HCVcc of genotype 1–6, depending on their affinity
for the antigen. Moreover, they observed a unidirectional
competition for binding to E2 between HC33 mAbs and
humanmAbs to the 434–446 amino acid region. In addition,
when neutralizing HC33 mAbs were combined with HC-11
or HC84 mAbs (whose epitopes encompass the proposed
“Antigenic Domain D” and have contact residues located
within the epitope II), they observed antagonistic effect at
lower Ab concentrations and synergistic effect at higher Ab
concentrations both in neutralization and NOB assays [47].
It is noteworthy that another recent paper supported the
possibility of Ab mediated interference in in vivo experi-
ments. In particular, treating an HCV chronically infected
chimpanzee using HCV1 mAb, the authors observed an
interfering effect, probably Ab mediated, of the chimpanzee
serum on the neutralizing activity of HCV1. In fact, similar
to AP33, HCV1 recognizes the epitope I region of E2 with a
comparable affinity [91].
Furthermore, recent clinical trials on HCV genotype 1a-
infected patients undergoing liver transplantation evidenced
a viral rebound after 28 and 2 days after transplantation
in mAb HCV1-treated patients and placebo-treated patients,
respectively. The authors observed the occurrence of viral
variants within the epitope I region that could determine
escape from HCV1 neutralization [92]. However, possi-
ble patient-interfering Abs could negatively influence the
neutralizing activity of the mAb, but the authors did not
investigate on this possible escape mechanism.
4.3. Topography of HCV/E2 Epitope II. As anticipated, dif-
ferently from the highly conserved nature of epitope I,
epitope II is less conserved as it is located within the third
hypervariable region of E2 (HVR3), which encompasses also
another neutralizing CD81 binding region, suggesting the
conformation-sensitive nature of epitope II [18].
In this regard, Duan et al. finely mapped the amino acid
residues of epitope II bound by nonneutralizing/interfering
Abs. In particular they isolated four mouse mAbs, two of
which (#8 and #41) were able to neutralize in vitro HCV
of genotype 1a, while the other two (#12 and #50) failed to
neutralize the virus. Interestingly, #12 mAb could interfere
with the neutralizing activity of a chimpanzee polyclonal Ab
and of a specific human immunoglobulin preparation both
directed against epitope I of HCV/E2. The authors predicted
indeed that residues W437, L438, and L441 (located within
epitope II) were the common direct contact points for the
binding of #8, #41, #12, and #50 mAbs. Interestingly, #12 and
#50 binding was more affected by substitution at L441 and
F442 than #8 and #41, suggesting that these residues may be
more related to the binding of nonneutralizing Abs rather
than that of neutralizing Abs (Table 1) [40]. Moreover, in a
recent work Deng et al., attempting to better define at the
atomic level the fundamental mechanism of Ab-mediated
neutralization, reported the crystal structure of the epitope
II peptide in complex with mAb #8. In particular, this group
found that mAb #8 interacts both with the C-terminal 𝛼-
helix (contacting aminoacid residues W437 and L438) and
the N-terminal loop (contacting aminoacid residues E431
and N434) of epitope II. Indeed the authors speculated
that neutralization may be achieved through bifurcated Ab-
binding to these two regions, compared to nonneutralizing
Abs which simply bind only 𝛼-helical structure of epitope II
[41].
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In this regard, conducting a meta-analysis of the data
reported by Duan et al., we can observe that substitutions
at W437 and F442 affected also e20, e137, and e509 binding,
while substitutions at L438 and L441 affected only e137
and e509 binding, again confirming the speculations of the
authors that both L441 and F442 are determinant for the
binding of nonneutralizing and interfering Abs [40, 49, 50,
52].
Finally, the predicted recognition of W437 by e20
and e137 does not limit their cross-recognition and cross-
neutralization profile of different genotypes/isolates as con-
versely observed by Duan et al. [40]. Further analysis on
the binding of these two cross-neutralizing mAbs to the N-
terminal loop of epitope II must be conducted. However,
similar to other previously described broadly neutralizing
mAbs, the neutralization mechanism of e20 and e137 appear
to be mediated by recognition of different discontinuous
conformational epitopes involving amino acid regions 412–
424, 436–447, and 523–540 of HCV/E2 glycoprotein [42, 52].
In fact, as suggested by Lapierre et al., broadly neutralizing
activity of these mAbs is the result of the recognition of
structural determinants rather than specific residues of the
conformational epitope II [90]. These speculations raise the
possibility that residues L441 and F442 are both contact
residues only for e509 and thus confirming that the sequence
441-LFY-443was linked to the non-neutralization of the virus
[40].
However, the role (and the existence itself) of interfering
Abs in influencing HCV infection is still controversial and, as
concluded by the authors themselves, caution must be taken
in differentiating neutralizing Abs from nonneutralizing
Abs solely on the basis of their residue specificity. Indeed,
minor change of residues in the Ab-antigen interface, epitope
frameshifting among genotypes/isolates, as well as change in
binding affinitymay alter recognition capabilities of theseAbs
and thereby may consequently modulate their activity [40].
Interestingly, according to the putative model for E2
folding, all the three aforementioned regionswould lie next to
each other on the glycoprotein [23].Therefore, this structural
prediction possibly supports the interfering effect of epitope
II-directed Abs. However while this predicted structure is
currently the best model available, these conclusions cannot
be absolutely asserted. For this purpose, the availability of E1-
E2 crystal will certainly accelerate the fine elucidation of the
spatial proximities of neutralizing and interfering epitopes
on the E1-E2 structure and, consequently, structure-based
vaccine progress.
Finally, the low prevalence and the low titer of epitope
I-reactive Abs in sera from both chronic and acute resolved
infections further support the hypothesis of a conformational
masking by adjacent regions such as epitope II [71, 89].
In fact, Zhang et al. originally put forward the idea that
once epitope II is bound to an Ab, the site of epitope I
becomes masked and can no longer be recognized by specific
neutralizing Abs. Indeed, depletion of Abs to epitope II
in plasma from a chronically infected HCV patient and
vaccinated chimpanzees recovered an otherwise undetectable
cross-genotype neutralizing activity [89]. Another possibility
is that the initial binding of interfering Abs to the region
containing epitope II may induce conformational changes
on E2 that inhibit the binding by epitope I-directed Abs, as
recently suggested by Lapierre et al. for other anti-HCV/E2
Abs [90].
Thus, the described divergent observations reported
above may depend on the different Ab specificities present
in the polyclonal preparations used and, probably, also on
the different HCV genotypes infecting the considered cohort
of patients. Moreover, the different strategies adopted in
isolating epitope I- and epitope II-directed Abs could explain
the different data obtained. In fact, immunoglobulins puri-
fied on peptides representing distinct HCV/E2 regions are
obviously directed against linear epitopes; these preparations
are certainly different from mAbs cloned using a full-length
HCV/E2 glycoprotein, which are more probably directed
against conformational epitopes including also residues out-
side the investigated linear regions.
To summarize, in the HCV field several works support
the existence of interfering Ab populations and hypothesize
their possible role inHCVpersistence, as demonstrated using
different Ab preparations such as human plasma-derived
immunoglobulin preparations, human mAbs, and sera of
animals immunized with recombinant HCV/E2 peptides.
The possible mechanism leading to the interference is still
controversial, but both direct steric-hindrance and induced
antigen conformational changes have been hypothesized. On
the other hand, other papers do not confirm these findings,
suggesting that the putative interfering epitope II may be
targeted by Abs endowed with a broadly neutralizing activity.
However other studies suggest that the interfering Abs do
exist but that their overall effectmay be biased by the presence
of neutralizing Abs with different binding features and by the
infecting HCV genotype. Future works further investigating
the in vivo role of these interferingAb subpopulations inHCV
persistence are certainly needed.
5. Conclusions
Althoughmuch of the research into neutralizing epitopes has
focused on the E2 glycoprotein, some neutralizing determi-
nants have been identified also in E1. Efforts to identify anti-
E1 Abs have been hindered by the poor folding of E1 when
expressed in vitro [93]. Despite this, mAbs directed to E1
192–211 amino acid region have been identified to be cross-
reactive with E1 samples representingmultiple genotypes and
neutralize entry [94], while neutralizing mAbs IGH505 and
IGH526 recognize an epitope between the 313–327 amino
acid region of E1 and neutralize entry of diverse isolates [95].
However, immunization with E1 alone does not induce a
neutralizing response in experimental animals [53]. Although
E1 is an interesting target for discovery of neutralizing Abs,
the current paucity of Abs directed to this protein limits
greater understanding of its antigenic structure.
Furthermore, the escape mechanism utilizing the elicita-
tion of nonneutralizing Ab subpopulations able to enhance
the viral infectivity or able to interfere with the activity of
neutralizing Abs has further implications in vaccine design
as well as in the development of effective therapeutic mAbs
[83]. Indeed, many anti-HCV/E2 mAbs recently described in
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the literature as well as those currently undergoing clinical
trials target regions that could potentially be subjected to the
Ab-mediated interfering mechanism [92]. Moreover, other
mechanisms of HCV escape from the humoral immune
response must be taken into account when considering the
potential clinical applications of developing antiviral mAbs
such as the lipoprotein and glycan shielding of the viral
envelope as well as the recently described glycan shifting con-
sequent to the high mutation rate of the virus [36], the main
reason for incomplete effectiveness of currently available
therapies aswell as themain hurdle for candidate therapeutics
under development. Finally, the observed cell-to-cell route
of infection for HCV may further limit the breadth of
viral entry inhibitors (e.g., anti-E1 and anti-E2 mAbs) in
particular in those chronically infected patients undergoing
liver transplantation with the consequent augmented risk
of graft reinfection and indeed of a more progressive and
complicated disease [96]. However, Abs able to neutralize this
route of transmission have been recently described [76]. On
the other hand, a further therapeutic approach overwhelming
these escapemechanismswould consist in the administration
of entry inhibitors together with other antiviral compounds
targeting different steps of the viral replication cycle such as
protease and polymerase inhibitors [97, 98]. In fact, it is well
known that in the treatment of chronic diseases caused by
hypervariable infectious agents, the administration of single
or multiple drugs targeting only limited step of their life cycle
leads, in the majority of cases, to the occurrence of escape
variants limiting their effectiveness that could be further
complicated by an incomplete adherence of the patients to
the therapeutic regimen. In this regard, the occurrence of
viral variants after treatment of HCV chronic infections
with the newly introduced protease inhibitors (Boceprevir
and Telaprevir), whose administration is indicated only for
genotype 1 infected patients, has beenwell demonstrated [99].
However, new more effective antiviral drugs targeting the
NS3 protein and other viral proteins as well as other cellular
targets implicated in the HCV viral life cycle, such as the
CD81 receptor, are under development and clinical evaluation
[100]. Interestingly, anti-CD81 compounds have shown to
limit the cell-to-cell spread of HCV and thus represent valu-
able candidates for a future combined therapy [101]. More-
over, differently from currently available therapies, the target-
ing of cellular determinants, such as CD81, may be theoreti-
cally beneficial for patients infected with any HCV genotype
and could be less subjected to the occurrence of viral variants.
Thus, the HCV entry inhibition by antivirals directed against
viral and cellular determinants could be an effective and
valuable tool, in particular in the course of a post-transplant
setting, for which no therapies are currently available.
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